Evidence and Access Archives

Publication

Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States

Authors: Joseph McGuirk, Clint Divine, Seung Hyun Moon, Aastha Chandak, Zhiji Zhang, Genovefa A. Papanicolaou…

Jim Gallagher2021 年 4 月 8 日

Article

Legislators: Bring all stakeholders to the table to lower drug costs

BY ROMAN CASCIANO, OPINION CONTRIBUTOR — 03/29/21 05:30 PM EDT No one is happy with the…

Certara2021 年 3 月 30 日

On-Demand Webinar

战略证据与价值传播研讨会

Join us on 2021 年 4 月 21 日, 星期三, from12:00 PM – 2:00 PM EDT for Certara’s…

Certara2021 年 3 月 26 日

Blog

为患者提供基因疗法

This blog discusses the challenges that drug developers face in getting patients access to cell…

Certara2021 年 2 月 16 日

Case Study

基因治疗临床试验设计中的早期价值评估

A global biotechnology company engineering precision genetic medicine for rare diseases was in need of…

Jim Gallagher2021 年 2 月 12 日

Article

Getting Real with RWE

By Taren Grom Real-world evidence, important for regulatory decision-making, is beginning to touch all areas…

Certara2020 年 11 月 20 日

On-Demand Webinar

SNDS: Strengths, Limitations and Perspectives for the Largest and Richest Real-World Database in EU

In this webinar, our experts provided an overview of the SNDS and the key working…

Jim Gallagher2020 年 10 月 20 日

Case Study

Reimbursement and Launch Planning

Jieun Choe2020 年 6 月 22 日

网络研讨会点播

罕见病药物困境：价值大、价格高、准入受限？

This webinar will explain how pricing has evolved for the rare disease drug market and…

Danielle Pillsbury2020 年 2 月 19 日

On-Demand Webinar

快速跟踪罕见病药物的创新解决方案

This webinar discussed which pharmaceutical payer strategies work and which don't in our rapidly changing…

Danielle Pillsbury2019 年 8 月 10 日

证据和准入

Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States

Legislators: Bring all stakeholders to the table to lower drug costs

战略证据与价值传播研讨会

为患者提供基因疗法

基因治疗临床试验设计中的早期价值评估

Getting Real with RWE

SNDS: Strengths, Limitations and Perspectives for the Largest and Richest Real-World Database in EU

Reimbursement and Launch Planning

罕见病药物困境：价值大、价格高、准入受限？

快速跟踪罕见病药物的创新解决方案

订阅时事通讯

快捷链接

解决方案

联系我们